Related Experiment Video
Updated: Feb 24, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Decreased Survival With Mastectomy Vis-à-Vis Breast-Conserving Surgery in Stage II and III Breast Cancers: A
Ambakumar Nandakumar1, Goura Kishor Rath1, Amal Chandra Kataki1
1, , , , , , National Centre for Disease Informatics and Research; , Apollo Hospitals; , HealthCare Global-Bangalore Institute of Oncology; , St John's Medical College; , International Medical School-MS Ramaiah Medical College, Bangalore; , Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi; , Dr B.B. Borooah Cancer Institute, Guwahati; , Healis-Sekhsaria Institute of Public Health, Navi Mumbai; , Amrita Institute of Medical Sciences and Research Centre, Kochi; , Postgraduate Institute of Medical Education and Research, Chandigarh; and , Cancer Centre Welfare Home and Research Institute, Kolkata, India.
Purpose:
The primary purpose of hospital-based cancer registries is assessing patient care. Clinical stage-based survival and treatment-based survival are some of the key parameters for such assessment. Because of the challenges in obtaining follow-up parameters, a separate study on patterns of care and survival was undertaken by the Indian National Cancer Registry Program. The results for cancer of the female breast are presented here.
Patients And Methods:
Data abstracted in a standardized patient information form were transmitted online to a central repository. Treatment patterns were assessed for 9,903 patients diagnosed between January 1, 2006, and December 31, 2008, from 13 institutions. Survival analysis was restricted to 7,609 patients from nine institutions wherein follow-up details (as of December 31, 2012) were available for at least 60% of patients.
Results:
The overall 5-year survival rates with breast-conserving surgery (BCS) and mastectomy (MS) were 94.0% and 85.8%, respectively, for stage II disease (adjusted hazard ratio, 2.40; 95% CI, 1.8 to 3.2) and 87.1% and 69.0%, respectively, for stage III disease (hazard ratio, 2.82; 95% CI, 2.2 to 3.7). Patients who had MS did better with systemic therapy (chemotherapy and/or hormone therapy), whereas patients with BCS required just local radiation therapy to achieve best survival.
Conclusion:
This observational study in the natural setting of care of patients with cancer in India showed significantly decreased survival with MS when compared with BCS. The reasons for lower survival with MS and the biologic or scientific rationale of the necessity of systemic therapy to achieve optimal survival in patients undergoing MS but not in those with BCS need further investigation.
More Related Videos
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
Cancer Survival Analysis
Kaplan-Meier Approach
Comparing the Survival Analysis of Two or More Groups